The ethics of disclosing genetic diagnosis for Alzheimers disease: Do we need a new paradigm?

British Medical Bulletin

Volumn 100, Issue 1, 2011, Pages 7-21

  Arribas Ayllon, Michael ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alzheimers disease; diagnosis; ethics; genetic complexity; genetic risk; genetic testing; susceptibility

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; HUNTINGTON CHOREA; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; ETHICS, MEDICAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; TRUTH DISCLOSURE;

EID: 83255174033     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldr023     Document Type: Article

References (80)

1. Tibben A, Vegter-van der Vlis M, Skraastad MI et al. DNA-testing for Huntington's disease in The Netherlands: a retrospective study on psychosocial effects. Am J Med Genet 1992;44:94-9.
2. Chapple A, May C, Campion P. Parental guilt: the part played by the clinical geneticist. J Genet Couns 1995;4:179-91.
3. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a study of emotional impact. J Med Genet 2001;38:519-26. (Pubitemid 32751580)
4. Murakami Y, Gondo N, Okamura H et al. Guilt from negative genetic test findings. Am J Psychiatry 2001;8:1929. (Pubitemid 33054793)
5. Featherstone K, Bharadwaj A, Clarke A et al. Risky Relations. Family and Kinship in the Era of New Genetics. Oxford: Berg Publishers, 2006.
6. Arribas-Ayllon M, Sarangi S, Clarke A. Managing self responsibility through other-oriented blame: family accounts of genetic testing. Soc Sci Med 2008;66:1521-32. (Pubitemid 351625417)
7. Parsons E, Atkinson P. Lay constructions of genetic risk. Sociol Health Illn 1992;14:437-55.
8. Miller OJ. Genetic counselling: meeting today's and tomorrow's needs. Birth Defects Orig Artic Ser 1970;6:76-9.
9. Lappé M. Genetic counselling and genetic engineering. Hasting Center Rep 1971;3:13-4.
10. Hilton B. Will the baby be normal? And what is the cost of knowing. Hasting Center Rep 1972;2:8-9.
11. Lappé M, Gustafson JM, Roblin R. Ethical and social issues in screening for genetic disease. N Engl J Med 1972;286:1129-32.
12. Gaylin W. Genetic screening: the ethics of knowing. N Engl J Med 1972;286:1361-2.
13. Hsia EY. Choosing my children's genes: genetic counselling. In: Lipkin M, Rowley PT (eds). Genetic Responsibility: On Choosing Our Children's Genes. New York: Plenum Press, 1974.
14. Fox RC. Advanced medical technology: social and ethical implications. Ann Rev Sociol 1976;2:231-68.
15. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, Screening and Counseling for Genetic Conditions. A Report on the Ethical, Social, and Legal Implications of Genetic Screening, Counseling, and Education Programs. Washington, DC: Government Printing Office, 1983.
16. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, 1979.
17. Powledge TM, Fletcher J. Guidelines for the ethical, social, and legal issues in prenatal diagnosis. N Engl J Med 1979;300:168-72.
18. Rowley PT. Genetic screening: marvel or menace? Science 1984;225:138-44.
19. Kessler S. The genetic counsellor as psychotherapist. Birth Defects Orig Artic Ser 1979;15:187-200.
20. Beauchamp TL. Ethical theory and bioethics. In: Beauchamp T, Walters L (eds). Contemporary Issues in Bioethics, 2nd edn. Belmont, CA: Wadsworth, 1982,1-43.
21. Toulmin S. The tyranny of principles. Hastings Center Rep 1981;11:31-39.
22. Bruyn GW. Diseases of the basal ganglia. In: Vinken PJ, Bruyn GW (eds). Handbook of Clinical Neurology, Vol 6. Amsterdam: North Holland, 1968.
23. Gusella JF, Wexler NS, Conneally PM et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-8. (Pubitemid 14232350)
24. Hemphill M. Tests for presymptomatic Huntington's chorea. N Engl J Med 1972;287:823.
25. Falck A. Issues and ethics in genetic counseling with Huntington's disease families. Psychiatr Forum 1973;4:51-60.
26. Craufurd DIO, Harris R. Ethics of predictive testing for Huntington's chorea. The need for more information. Br Med J 1986;293:249-51.
27. Terrenoire G. Huntington's disease and the ethics of genetic prediction. J Med Ethics 1992;18:79-85.
28. Thomas S. Ethics of a predictive test for Huntington's chorea. Br Med J 1982;284:1383-5. (Pubitemid 12155394)
29. Bloch M, Hayden MR. Predictive testing for Huntington's disease in childhood: challenges and implications. Am J Med Genet 1990;46:1-4. (Pubitemid 20033535)
30. Crauford D, Dodge A, Kerzin-Storrar L et al. Testing of children for 'adult' genetic diseases (letter). Lancet 1990;335:1406.
31. Harper PS, Clarke A. Should we test children for 'adult' genetic disease? Lancet 1990;335:1205-6. (Pubitemid 20171382)
32. Macdonald ME, Ambrose CM, Duyao MP et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83. (Pubitemid 23110238)
33. Schoenfeld M, Myers RH, Cupples LA et al. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:1283-7. (Pubitemid 15178748)
34. Kessler S. Psychiatric implications of presymptomatic testing for Huntington's disease. Am J Orthopsychiatry 1987;57:212-9. (Pubitemid 17129836)
35. Lam RW, Bloch M, Jones BD et al. Psychiatric morbidity associated with early clinical diagnosis of Huntington disease in a predictive testing program. J Clin Psychiatry 1988;49:444-7.
36. Wiggins S, Whyte P, Huggins M et al. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med 1992;327:1401-5.
37. Wertz DC, Fletcher JC. Ethics and medical genetics in the United States: a national survey. Am J Med Genet 1988;29:815-27.
38. Chapman MA. Predictive testing for adult-onset genetic disease: ethical and legal implications of the use of linkage analysis for Huntington's disease. Am J Hum Genet 1990;47:1-3.
39. Wertz DC, Fletcher JC. Privacy, disclosure, and discrimination: surveys of U.S. geneticists and public. Am J Hum Genet 1995;57:A229.
40. Tyler A, Harper PS. Attitudes of subjects at-risk and their relatives towards genetic counselling in Huntington's chorea. J Med Genet 1983;20:179-88. (Pubitemid 13055227)
41. Mastronmauro C, Myersa RH, Berkman B. Attitudes towards predictive testing in Huntington's disease. Am J Med Genet 1987;26:271-82.
42. Meissen GJ, Berchek RL. Intentions to use predictive testing by those at risk for Huntington's disease: implications for prevention. Am J Community Psychol 1988;16:261-77.
43. World Federation of Neurology Research Group on Huntington's Disease. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Neurol Sci 1989;94:327-32.
44. World Federation of Neurology Research Group on Huntington's Disease. Ethical issues policy statement on Huntington's disease molecular genetics predictive test. J Med Genet 1990;27:34-8.
45. World Federation of Neurology Research Group on Huntington's Disease. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994;555-9.
46. Wexler N. The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders. Fed Am Soc Exp Biol J 1992;6:2820-5.
47. DuBose ER, Hamel RP, O'Connell LJ (eds). A Matter of Principles? Ferment in U.S. Bioethics. Valley Forge, PA: Trinity Press International, 1994.
48. Evans JH. A sociological account of the growth of principlism. Hastings Center Rep 2000;30:31-38.
49. Boddington P, Hogben S. Working up policy: the use of specific disease exemplars in formulating general principles governing childhood genetic testing. Health Care Anal 2006;14:1-13. (Pubitemid 44560851)
50. Corder EH, Saunders AH, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
51. Roberts JS, Barber M, Brown TM et al. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004;6:197-203. (Pubitemid 39005859)
52. Brodaty H, Conneally M, Gauthier S et al. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9:182-214.
53. Farrer LA, Brin MF, Elsas L et al. Statement on the use of apoliopoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-9.
54. Post SG, Whitehouse PJ, Binstock RH et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997;277:832-6. (Pubitemid 27111321)
55. Burgess M. Ethical issues in genetic testing for Alzheimer's disease: lessons from Huntington's disease. Alzheimer Dis Assoc Disord 1994;8:71-8. (Pubitemid 24143846)
56. Quaid KA. 'Implications of genetic susceptibility testing with apolipoprotein E'. In: Post S, Whitehouse P (eds). Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore and London: John Hopkins Press, 1998,118-40.
57. Ball DM, Harper PS. Presymptomatic testing for late-onset genetic disorders: lessons from Huntington's disease. Fed Am Soc Exp Biol J 1992;6:2818-9.
58. Hedgecoe A. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge: Cambridge University Press, 2004.
59. McConnell LM, Koenig B, Greely H et al. Genetic testing and Alzheimer's disease: has the time come? Nat Med 1998;4:757-9.
60. McConnell LM, Sanders GD, Owens DK. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer's disease. Genet Test 1999;3:47-53. (Pubitemid 29239635)
61. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease. Ann Neurol 1995;38:6-14.
62. Roses AD. Genetic testing for Alzheimer disease: practical and ethical issues. Arch Neurol 1997;54:1226-9. (Pubitemid 27452237)
63. Roses AD. 'A new paradigm for clinical evaluation of dementia: Alzheimer disease and Apolioproteiin E genotpyes'. In: Post S, Whitehouse P (eds). Genetic Testing for Alzheimer's Disease: Ethical and Clinical Issues. Baltimore and London: John Hopkins Press, 1998,37-64.
64. Julian-Reynier C, Welkenhuysen M, Hagoel L et al. Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet 2003;11:725-36. (Pubitemid 37337054)
65. Green RC, Roberts SJ, Cupples AL et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-54.
66. Marteau TM, Roberts S, LaRusse S et al. Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal 2005;25:397-404. (Pubitemid 40664366)
67. Cassidy MR, Roberts SJ, Bird TD et al. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimer's Dement 2008;4:406-13.
68. Locke M, Freeman J, Chilibeck G et al. Susceptibility genes and the question of embodied identity. Med Anthropol Q 2007;21:256-76.
69. Chao S, Roberts JS, Marteau TM et al. Health behaviour changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord 2008;22:94-7. (Pubitemid 351651404)
70. Slovic P. Perceived risk, trust, and democracy. Risk Anal 1993;13:675-82. (Pubitemid 24012162)
71. Slovic P, Fischhoff B, Lichenstein S. Facts and fears: understanding perceived risk. In: Schwing RC, Albers WA (eds). Societal Risk Assessment: How Safe is Safe Enough? New York: Plenum Press, 1980.
72. Lippman-Hand A, Fraser FC. Genetic counselling: parents' responses to uncertainty. Birth Defects Orig Artic Ser 1979;XV:325-39. (Pubitemid 10162398)
73. Chilibeck G, Lock M, Sehdev M. Postgenomic, uncertain futures, and the familiarization of susceptibility genes. Soc Sci Med (corrected proof), 2010.
74. Michie S, Weinman J, Miller J et al. Predictive genetic testing: high risk expectations in the face of low risk information. J Behav Med 2002;25:33-50. (Pubitemid 37489850)
75. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effects on physicians willingness to prescribe. Lancet 1994;343:1209-11. (Pubitemid 24147560)
76. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994;309:761-4. (Pubitemid 24291634)
77. Saukko PP, Richards SH, Shepherd MH et al. Are genetic tests exceptional? Lessons from a qualitative study on thrombophilia. Soc Sci Med 2006;63:1947-59. (Pubitemid 44176171)
78. Eckert SL, Katzen H, Roberts JS et al. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med 2006;8:746-51. (Pubitemid 44973762)
79. Ashida S, Koehly LM, Roberts JS et al. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun 2009;14:768-84.
80. Codori AM, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet 1994;54:174-84. (Pubitemid 24292178)